Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Enterprise Value (2022 - 2025)

Historic Enterprise Value for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$138.0 million.

  • Phathom Pharmaceuticals' Enterprise Value rose 5911.06% to -$138.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$138.0 million, marking a year-over-year increase of 5911.06%. This contributed to the annual value of -$300.1 million for FY2024, which is 2189.45% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Enterprise Value stood at -$138.0 million, which was up 5911.06% from -$152.4 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Enterprise Value registered a high of -$130.1 million during Q1 2023, and its lowest value of -$384.3 million during Q4 2023.
  • For the 4-year period, Phathom Pharmaceuticals' Enterprise Value averaged around -$228.5 million, with its median value being -$215.2 million (2025).
  • Its Enterprise Value has fluctuated over the past 5 years, first crashed by 14992.2% in 2024, then soared by 5911.06% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Enterprise Value (Quarter) stood at -$155.9 million in 2022, then plummeted by 146.49% to -$384.3 million in 2023, then grew by 21.89% to -$300.1 million in 2024, then surged by 54.01% to -$138.0 million in 2025.
  • Its Enterprise Value stands at -$138.0 million for Q3 2025, versus -$152.4 million for Q2 2025 and -$215.2 million for Q1 2025.